APA

Black J., Menderes G., Bellone S., Schwab C. L., Bonazzoli E., Ferrari F., Predolini F., De Haydu C., Cocco E., Buza N., Hui P., Wong S., Lopez S., Ratner E., Silasi D., Azodi M., Litkouhi B., Schwartz P. E., Goedings P., Beusker P. H., van der Lee M. M. C., Timmers C. M., Dokter W. H. A. & Santin A. D. (20170629). SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. : Molecular cancer therapeutics.

Chicago

Black Jonathan, Menderes Gulden, Bellone Stefania, Schwab Carlton L, Bonazzoli Elena, Ferrari Francesca, Predolini Federica, De Haydu Christopher, Cocco Emiliano, Buza Natalia, Hui Pei, Wong Serena, Lopez Salvatore, Ratner Elena, Silasi Dan-Arin, Azodi Masoud, Litkouhi Babak, Schwartz Peter E, Goedings Peter, Beusker Patrick H, van der Lee Miranda M C, Timmers C Marco, Dokter Wim H A and Santin Alessandro D. 20170629. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. : Molecular cancer therapeutics.

Harvard

Black J., Menderes G., Bellone S., Schwab C. L., Bonazzoli E., Ferrari F., Predolini F., De Haydu C., Cocco E., Buza N., Hui P., Wong S., Lopez S., Ratner E., Silasi D., Azodi M., Litkouhi B., Schwartz P. E., Goedings P., Beusker P. H., van der Lee M. M. C., Timmers C. M., Dokter W. H. A. and Santin A. D. (20170629). SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. : Molecular cancer therapeutics.

MLA

Black Jonathan, Menderes Gulden, Bellone Stefania, Schwab Carlton L, Bonazzoli Elena, Ferrari Francesca, Predolini Federica, De Haydu Christopher, Cocco Emiliano, Buza Natalia, Hui Pei, Wong Serena, Lopez Salvatore, Ratner Elena, Silasi Dan-Arin, Azodi Masoud, Litkouhi Babak, Schwartz Peter E, Goedings Peter, Beusker Patrick H, van der Lee Miranda M C, Timmers C Marco, Dokter Wim H A and Santin Alessandro D. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. : Molecular cancer therapeutics. 20170629.